Sagimet Biosciences Inc. Files Amendment to S-1 Registration Statement

TL;DR

<b>Sagimet Biosciences Inc. has filed an amendment to its S-1 registration statement, indicating progress towards a public offering.</b>

AI Summary

Sagimet Biosciences Inc. (SGMT) filed a Amended IPO Registration (S-1/A) with the SEC on January 24, 2024. Sagimet Biosciences Inc. filed an amendment (S-1/A) to its registration statement on January 24, 2024. The company is incorporated in Delaware and its principal executive offices are located in San Mateo, California. The filing is under the Securities Act of 1933, with registration number 333-276664. David Happel is listed as President and Chief Executive Officer. The filing includes legal counsel from Goodwin Procter LLP and Cooley LLP.

Why It Matters

For investors and stakeholders tracking Sagimet Biosciences Inc., this filing contains several important signals. This amendment suggests Sagimet Biosciences is moving forward with its plans to become a publicly traded company, which could provide access to capital for its operations and research. The filing provides updated information for potential investors, detailing the company's structure, key personnel, and legal representation involved in the offering.

Risk Assessment

Risk Level: low — Sagimet Biosciences Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, which is a standard procedural step for companies pursuing an IPO and does not inherently indicate significant new risks.

Analyst Insight

Monitor future filings for details on the offering size, pricing, and use of proceeds to assess investment potential.

Key Numbers

• 2024-01-24 — Filing Date (Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT)
• 333-276664 — SEC File Number (Registration Statement Number)
• 1933 — Securities Act Year (Form S-1 filed under)
• 2834 — SIC Code (Primary Standard Industrial Classification Code Number)
• 20-5991472 — IRS Number (I.R.S. Employer Identification Number)
• 155 Bovet Road, Suite 303 — Principal Office Address (Registrant's business address)
• 94402 — Principal Office Zip Code (Registrant's business address)
• (650) 561-8600 — Business Phone (Registrant's telephone number)

Key Players & Entities

• Sagimet Biosciences Inc. (company) — Registrant
• 2024-01-24 (date) — Filing date
• 333-276664 (registration_number) — SEC File Number
• Delaware (jurisdiction) — State of incorporation
• San Mateo, California (location) — Principal executive offices
• David Happel (person) — President and Chief Executive Officer
• Goodwin Procter LLP (company) — Legal counsel
• Cooley LLP (company) — Legal counsel

Forward-Looking Statements

• Sagimet Biosciences Inc. will complete its initial public offering (IPO) (Sagimet Biosciences Inc.) — high confidence, target: Q1 2024

FAQ

Industry Context

Sagimet Biosciences operates in the pharmaceutical preparations industry, focusing on the development of novel therapeutics.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.

What Investors Should Do

1. Review the full S-1/A filing for detailed financial information and business strategy.
2. Track subsequent SEC filings for updates on the IPO timeline and offering details.
3. Research the company's drug pipeline and clinical trial progress.

Key Dates

• 2024-01-24: Filing of Amendment No. 1 to Form S-1 — Indicates progress in the registration process for a public offering.

Year-Over-Year Comparison

This is an amendment to a previously filed registration statement, indicating ongoing procedural steps rather than a direct comparison to a prior period's financial performance.

Key Financial Figures

• $18.42 — n stock on the Nasdaq Global Market was $18.42 per share. We are an "emerging growth
• $94.9 million — December 31, 2023, we had approximately $94.9 million of cash, cash equivalents and short-ter

Filing Documents

• tm2333216-10_s1a.htm (S-1/A) — 3718KB
• tm2333216d11_ex5-1.htm (EX-5.1) — 8KB
• tm2333216d11_ex23-1.htm (EX-23.1) — 2KB
• tm2333216d11_ex5-1img01.jpg (GRAPHIC) — 4KB
• lg_sagimet-4c.jpg (GRAPHIC) — 18KB
• bc_leaddrug-4clr.jpg (GRAPHIC) — 42KB
• bc_weekdosing-4c.jpg (GRAPHIC) — 35KB
• bc_pipeline-4c.jpg (GRAPHIC) — 72KB
• fc_overview-4c.jpg (GRAPHIC) — 34KB
• fc_patients-4c.jpg (GRAPHIC) — 54KB
• fc_excessliver-4c.jpg (GRAPHIC) — 27KB
• fc_denifanstat-4c.jpg (GRAPHIC) — 31KB
• fc_pathogenesis-4c.jpg (GRAPHIC) — 61KB
• fc_clinicaltrial4c.jpg (GRAPHIC) — 26KB
• bc_liverfatbio-4c.jpg (GRAPHIC) — 39KB
• bc_inflammation-4c.jpg (GRAPHIC) — 33KB
• bc_fibrosiss-4c.jpg (GRAPHIC) — 21KB
• fc_metabolic-4c.jpg (GRAPHIC) — 23KB
• fc_clinicaltrial-4c.jpg (GRAPHIC) — 29KB
• bc_biomarkerimaging-4c.jpg (GRAPHIC) — 29KB
• ph_denifanstat-4c.jpg (GRAPHIC) — 70KB
• bc_lipotoxicity-4c.jpg (GRAPHIC) — 45KB
• bc_fibrosisbio-4c.jpg (GRAPHIC) — 21KB
• bc_lipidbio-4c.jpg (GRAPHIC) — 22KB
• tb_treatment-4c.jpg (GRAPHIC) — 55KB
• bc_denifanstat-4c.jpg (GRAPHIC) — 13KB
• tb_fibrogenic-4c.jpg (GRAPHIC) — 27KB
• bc_collagen-4c.jpg (GRAPHIC) — 46KB
• fc_precision-4c.jpg (GRAPHIC) — 47KB
• bc_tripalmitin-4c.jpg (GRAPHIC) — 11KB
• lc_predictive-4c.jpg (GRAPHIC) — 17KB
• fc_diseaserationale-4c.jpg (GRAPHIC) — 53KB
• tb_oncology-4c.jpg (GRAPHIC) — 44KB
• bc_solidtumors-4c.jpg (GRAPHIC) — 36KB
• 0001104659-24-006039.txt (&nbsp;) — 5213KB

RISK FACTORS

RISK FACTORS 12 SPECIAL NOTE REGARDING FORWARD-LOOKING 65 MARKET, INDUSTRY AND OTHER DATA 67

USE OF PROCEEDS

USE OF PROCEEDS 68 DIVIDEND POLICY 69 CAPITALIZATION 70

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 74

BUSINESS

BUSINESS 85 MANAGEMENT 144 Page

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 153 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 167 PRINCIPAL STOCKHOLDERS 168

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 172 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS 176

UNDERWRITING

UNDERWRITING 180 LEGAL MATTERS 188 EXPERTS 188 WHERE YOU CAN FIND ADDITIONAL INFORMATION 188 INDEX TO FINANCIAL F-1 Neither we nor the underwriters have authorized anyone to provide you any information or make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our Series A common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside of the United States: we have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our Series A common stock and the distribution of this prospectus outside of the United States. Sagimet Biosciences Inc. and our logo are our trademarks and are used in this prospectus. This prospectus also includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, our trademarks and tradenames referred to in this prospectus appear without the symbol, but those references are not intended to indicate, in any way, that we will not ass

View Full Filing

View this S-1/A filing on SEC EDGAR